1	The association between prolonged SARS-CoV-2 symptoms and work outcomes
2	
3	Arjun Venkatesh, MD, MBA, MHS ^{1-2*} , Huihui Yu, PhD ² ; Caitlin Malicki, MPH ¹ ; Michael Gottlieb,
4	MD ³ ; Joann G. Elmore, MD, MPH ⁴ ; Mandy J. Hill, DrPH, MPH ⁵ ; Ahamed H. Idris, MD ⁶ ; Juan Carlos
5	C. Montoy, MD, PhD ⁷ ; Kelli N. O'Laughlin, MD, MPH ⁸ ; Kristin L. Rising, MD, MSHP ⁹⁻¹⁰ ; Kari A.
6	Stephens, PhD ¹¹⁻¹² ; Erica S. Spatz, MD, MHS ^{13-14¶} ; Robert A. Weinstein, MD ^{15-16¶} for the INSPIRE
7	Group^
8	
9 10 11	¹ Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America
12 13 14	² Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Yale School of Medicine, Connecticut, United State of America
15 16 17	³ Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, United States of America
18 19 20	⁴ Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, United States of America
21 22	⁵ Department of Emergency Medicine, UTHealth Houston, Houston, Texas, United States of America
23 24 25	⁶ Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
26 27 28	⁷ Department of Emergency Medicine, University of California, San Francisco, San Francisco, California, United States of America
29 30 31	⁸ Departments of Emergency Medicine and Global Health, University of Washington, Seattle, Washington, United States of America
32 33 34	⁹ Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
35 36 37	¹⁰ Center for Connected Care, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

38 39 40	¹¹ Department of Family Medicine, University of Washington, Seattle, Washington, United States of America
41 42 43	¹² Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, United States of America
44 45 46	¹³ Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, United States of America
47 48 49	¹⁴ Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America
50 51 52	¹⁵ Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, United States of America
53 54 55 56 57	¹⁶ Department of Medicine, Cook County Hospital, Chicago, Illinois, United States of America
58	*Corresponding author
59	Email: arjun.venkatesh@yale.edu (AKV)
60	
61 62 63	¶These authors are co-senior authors.

64 ^Membership of the INSPIRE Group is provided in Appendix 1.

65 Abstract

66 While the early effects of the COVID-19 pandemic on the United States labor market are well-67 established, less is known about the long-term impact of SARS-CoV-2 infection and Long COVID on 68 employment. To address this gap, we analyzed self-reported data from a prospective, national cohort 69 study to estimate the effects of SARS-CoV-2 symptoms at three months post-infection on missed 70 workdays and return to work. The analysis included 2,939 adults in the Innovative Support for Patients 71 with SARS-CoV-2 Infections Registry (INSPIRE) study who tested positive for their initial SARS-CoV-72 2 infection at the time of enrollment, were employed before the pandemic, and completed a baseline and 73 three-month electronic survey. At three months post-infection, 40.8% of participants reported at least 74 one SARS-CoV-2 symptom and 9.6% of participants reported five or more SARS-CoV-2 symptoms. 75 When asked about missed work due to their SARS-CoV-2 infection at three months, 7.1% of 76 participants reported missing >10 workdays and 13.9% of participants reported not returning to work 77 since their infection. At three months, participants with ≥ 5 symptoms had a higher adjusted odds ratio 78 (aOR) of missing \geq 10 workdays (2.96, 95% CI 1.81-4.83) and not returning to work (2.44, 95% CI 1.58-79 3.76) compared to those with no symptoms. Prolonged SARS-CoV-2 symptoms were common, 80 affecting 4-in-10 participants at three-months post-infection, and were associated with increased odds of 81 work loss, most pronounced among adults with >5 symptoms at three months. Despite the end of the 82 Federal COVID-19 Public Health Emergency and efforts to "return to normal", policymakers must 83 consider the clinical and economic implications of the COVID-19 pandemic on people's employment 84 status and work absenteeism, particularly as data characterizing the numerous health and well-being 85 impacts of Long COVID continue to emerge. Improved understanding of risk factors for lost work time 86 may guide efforts to support people in returning to work.

87 Introduction

The COVID-19 pandemic has resulted in tremendous economic dislocation in labor markets, creating historically volatile unemployment and reduced labor force participation rates due to unprecedented occupational health stresses and work loss [1]. Even as labor markets have stabilized in most countries including sustained periods of low unemployment [2], the economic impacts of the COVID-19 pandemic persist for many individuals as infections, hospitalizations and morbidity from SARS-CoV-2 infection continue.

94 Most prior research has examined the macroeconomic employment effects of the pandemic and 95 policy responses such as stay-at-home orders [3-4], with less investigation of the direct relationship 96 between SARS-CoV-2 illness and work. One small retrospective study conducted early in the pandemic 97 examining work outcomes among clinical cohorts reported that approximately half of individuals 98 hospitalized with SARS-CoV-2 were unable to return to work at six months [5]. A more recent study 99 using the US Current Population Survey found that work absences of up to one week due to acute 100 SARS-CoV-2 illness were associated with less labor force participation and more work absences one 101 year later, which is estimated to have reduced the US labor force by 500,000 people [6].

One possible mechanism for this long-term impact on employment is post-COVID conditions, which include a wide range of physical and mental health consequences that are present at least four weeks after SARS-CoV-2 infection [7-8]. Post-COVID conditions, often referred to as Long COVID, affect nearly one-in-five adults with a history of SARS-CoV-2 infection [9] and may make returning to work or seeking employment more difficult [10]. An unadjusted analysis of an international convenience sample recruited via social media found that most individuals with SARS-CoV-2 symptoms beyond 28 days reported a reduced work schedule, suggesting a relationship between prolonged symptoms

109	following an acute SARS-CoV-2 infection and short-term work loss [11]. However, the prevalence of
110	Long COVID and its impact on work outcomes, such as return to work and missed workdays, is poorly
111	understood [12].

To address this gap, we sought to utilize data from the Innovative Support for Patients with
 SARS-CoV-2 Infections Registry (INSPIRE) study to describe self-reported work outcomes related to
 acute SARS-CoV-2 infection and the presence of symptoms at three months post-infection.

115

116 Materials and methods

117 Study design

118 INSPIRE is a previously described prospective study designed to assess long-term symptoms and

119 outcomes among persons with COVID-like illness who tested positive versus negative for SARS-CoV-2

120 at study enrollment [13]. Participants were enrolled virtually or in-person across eight study sites,

121 including Rush University (Chicago, Illinois), Yale University (New Haven, Connecticut), the

122 University of Washington (Seattle, Washington), Thomas Jefferson University (Philadelphia,

123 Pennsylvania), the University of Texas Southwestern (Dallas, Texas), the University of Texas, Houston

124 (Houston, Texas), the University of California, San Francisco (San Francisco, California) and the

125 University of California, Los Angeles (Los Angeles County, California). Inclusion criteria included age

126 ≥18 years, fluency in English or Spanish, self-reported symptoms suggestive of acute SARS-CoV-2

127 infection at time of testing (e.g., fever, cough), and testing for SARS-CoV-2 with an FDA-

128 approved/authorized molecular or antigen-based assay within the preceding 42 days. Exclusion criteria

129 included inability to provide consent, being lawfully imprisoned, inability of the study team to confirm

130 the result of the index diagnostic test for SARS-CoV-2, having a previous SARS-CoV-2 infection >42

131	days before enrollment, and lacking access to an internet-connected device (e.g., smartphone, tablet,
132	computer) for electronic survey completion. Participants with a positive SARS-CoV-2 test (COVID-
133	positive) and a negative SARS-CoV-2 test (COVID-negative) were recruited in a 3:1 ratio. Following
134	electronic consent, participants completed a baseline survey and follow-up surveys every three months
135	for up to 18 months post-enrollment, although only baseline and three-month follow-up surveys were
136	included in this secondary analysis. The three-month survey was sent 76 days following enrollment,
137	which was up to 118 days after the positive SARS-CoV-2 test, and participants had a 28-day window to
138	complete the three-month survey.

139

140 Surveys

141 The baseline and three-month surveys included a variety of questions regarding sociodemographics,

142 SARS-CoV-2 symptoms and overall health to assess long-term symptoms and outcomes related to

143 COVID-like illness. To establish baseline employment status, the baseline survey asked, "Were you

144 employed before the coronavirus outbreak?", with the following response options: Yes; No. To establish

145 return to work status following a SARS-CoV-2 infection, the three-month survey asked, "Did you return

146 to work after your COVID-19 like symptoms?", with the following response options: Yes, full-time;

147 Yes, part-time or modified work; No; Not applicable. To establish workdays missed due to SARS-CoV-

148 2 infection, the three-month survey asked, "Since before you had COVID-19 like symptoms, how many

149 workdays or weeks did you miss because of health reasons?", with the following response options: I

don't work; 0-5 workdays; 6-10 workdays; 10-20 workdays; up to 4 weeks.

151 To assess SARS-CoV-2 symptoms at the time of survey completion, the baseline and three-152 month surveys asked, "Do you currently have any of the following ongoing symptoms? (Select all that 153 apply)", with the following response options: fever; feeling hot or feverish; chills; repeated shaking with

chills; more tired than usual; muscle aches; joint pains; runny nose; sore throat; a new cough, or
worsening of a chronic chough; shortness of breath; wheezing, pain or tightness in your chest;
palpitations; nausea or vomiting; headache; hair loss; abdominal pain; diarrhea (>3 loose/looser than
normal stools/24 hours); decreased smell or change in smell; decreased taste or change in taste; none of
the above.

159

160 Analysis

161 This analysis was restricted to COVID-positive participants who responded "yes" to being employed 162 prior to the pandemic on the baseline survey and completed the three-month survey. Unadjusted 163 comparisons in baseline characteristics and outcomes were made using chi-square tests among groups 164 with different numbers of symptoms $(0, 1-2, 3-4, \ge 5 \text{ symptoms})$. We examined the association of the 165 number of symptoms at three-months with return to work and health-related work absenteeism (days 166 missed ≥ 10) between enrollment and three-months using logistic regression models adjusting for age, 167 gender, race, ethnicity, income, marital status, education, clinical comorbidity count, and SARS-CoV-2 168 variant time period [14]. Covariates were included in the model based on existing literature and 169 unadjusted tests on the significance of association with outcomes. To categorize missed workdays, we 170 established a cutoff of greater than or equal to ten days based on the original design of survey response 171 options. All statistics and data analysis were performed in SAS 9.4.

172

173 **Results**

174 Survey Completion

- 175 Among 8,950 individuals who completed informed consent between December 2020 and August 2022,
- 176 6,049 were eligible for the three-month survey (Figure 1). A total of 4,588 participants completed the
- 177 three-month survey, with survey completion rates varying slightly between the COVID-positive (77%)
- and COVID-negative (71%) groups. Among COVID-positive three-month survey respondents only
- 179 (n=3,533), we analyzed data from the 2,939 participants (83.2%) who responded "yes" to being
- 180 employed prior to the pandemic on the baseline survey.
- 181

182 Participant Characteristics

- 183 The mean age was 40 years (SD 12.6), 64.1% were female, 69.5% were white, 61.2% were vaccinated
- 184 for SARS-CoV-2 before index test, and 3.8% were hospitalized for SARS-CoV-2 infection. 1,732
- 185 (59.2%) and 282 (9.6%) reported 0 and \geq 5 symptoms at three months, respectively (**Table 1**).

	Total	Number of Symptoms at 3 months (n, %)				
Characteristic	n=2928*	0	1-2	3-4	<u>≥</u> 5	p-value
n (%)		(1732, 59.2)	(677, 23.1)	(237, 8.1)	(282, 9.6)	-
Age						0.306
18-34	1210 (41.3)	750 (43.7)	269 (40)	87 (37)	104 (37)	
35-49	1019 (34.8)	581 (33.8)	249 (37.1)	88 (37.4)	101 (35.9)	
50-64	548 (18.7)	314 (18.3)	121 (18)	49 (20.9)	64 (22.8)	
65+	129 (4.4)	73 (4.2)	33 (4.9)	11 (4.7)	12 (4.3)	
Missing^	22 (0.8)					
Gender						<.001
Female	1878 (64.1)	1052 (62.5)	458 (69.4)	165 (72.7)	203 (73.3)	
Male	930 (31.8)	612 (36.4)	191 (28.9)	58 (25.6)	69 (24.9)	
Transgender/Non-Binary/Other	39 (1.3)	19 (1.1)	11 (1.7)	4 (1.8)	5 (1.8)	
Missing^	81 (2.8)					
Ethnicity						0.024
Non-Hispanic	2485 (84.9)	1494 (87.9)	565 (85)	190 (81.5)	236 (85.5)	
Hispanic	388 (13.3)	205 (12.1)	100 (15)	43 (18.5)	40 (14.5)	
Missing^	55 (1.8)					
Race						<.001
American Indian/Alaskan Native	18 (0.6)	11 (0.7)	2 (0.3)	1 (0.4)	4 (1.4)	
Asian/Native Hawaiian/Pacific Islander	389 (13.3)	249 (14.7)	92 (14)	24 (10.5)	24 (8.7)	
Black	189 (6.5)	103 (6.1)	32 (4.9)	26 (11.4)	28 (10.1)	
White	2036 (69.5)	1217 (72)	474 (72.3)	148 (64.9)	197 (71.1)	

Other	220 (7.5)	111 (6.6)	56 (8.5)	29 (12.7)	24 (8.7)	
Missing^	76 (2.6)					
Education						<.001
Less than High school	24 (0.8)	11 (0.6)	5 (0.8)	4 (1.7)	4 (1.4)	
High school graduate	129 (4.4)	64 (3.8)	28 (4.2)	20 (8.7)	17 (6.1)	
Some College	355 (12.1)	185 (10.9)	75 (11.3)	31 (13.4)	64 (22.9)	
2-year degree	189 (6.5)	88 (5.2)	47 (7.1)	27 (11.7)	27 (9.6)	
4-year degree	1018 (34.8)	621 (36.6)	228 (34.4)	74 (32)	95 (33.9)	
More than 4-year degree	1156 (39.5)	728 (42.9)	280 (42.2)	75 (32.5)	73 (26.1)	
Missing^	57 (1.9)					
Marital Status						<.001
Married	1665 (56.9)	994 (57.4)	397 (58.7)	124 (52.8)	150 (53.2)	
Divorced/Widowed/Separated	253 (8.6)	123 (7.1)	58 (8.6)	37 (15.7)	35 (12.4)	
Never married	1007 (34.4)	615 (35.5)	221 (32.7)	74 (31.5)	97 (34.4)	
Missing^	3 (0.1)					
Annual Family Income						<.001
<10,000	77 (2.6)	45 (2.6)	14 (2.1)	5 (2.1)	13 (4.6)	
10,000-34,999	271 (9.3)	137 (7.9)	59 (8.7)	36 (15.2)	39 (13.8)	
35,000-49,999	285 (9.7)	132 (7.6)	79 (11.7)	31 (13.1)	43 (15.2)	
50,000-74,999	391 (13.4)	217 (12.5)	102 (15.1)	32 (13.5)	40 (14.2)	
75,000+	1751 (59.8)	1105 (63.8)	393 (58.1)	125 (52.7)	128 (45.4)	
Prefer not to answer	152 (5.2)	96 (5.5)	29 (4.3)	8 (3.4)	19 (6.7)	
Missing^	1 (0)					
Health Insurance						<.001
Private	2378 (81.2)	1460 (84.3)	549 (81.1)	177 (74.7)	192 (68.1)	
Public	383 (13.1)	188 (10.9)	89 (13.1)	38 (16)	68 (24.1)	
Private and public	68 (2.3)	40 (2.3)	11 (1.6)	11 (4.6)	6 (2.1)	
None	99 (3.4)	44 (2.5)	28 (4.1)	11 (4.6)	16 (5.7)	
Housing						0.450
Unstable housing	25 (0.9)	12 (0.7)	6 (0.9)	4 (1.7)	3 (1.1)	
Stable housing	2898 (99)	1719 (99.3)	671 (99.1)	233 (98.3)	275 (98.9)	
Missing^	5 (0.1)					
Tobacco Use						<.001
Any tobacco use	385 (13.1)	221 (12.8)	68 (10)	40 (16.9)	56 (19.8)	
No tobacco use	2541 (86.8)	1510 (87.2)	609 (90)	196 (83.1)	226 (80.1)	
Missing^	2 (0.1)					
Comorbidities						
Asthma	331 (11.3)	156 (9.1)	78 (11.6)	44 (19)	53 (19.6)	<.001
Hypertension	330 (11.3)	175 (10.2)	72 (10.7)	34 (14.7)	49 (18.1)	<.001
Diabetes	118 (4)	69 (4)	27 (4)	13 (5.6)	9 (3.3)	0.613
Obesity	763 (26.1)	397 (23.2)	179 (26.7)	93 (40.3)	94 (34.8)	<.001
Emphysema/COPD	47 (1.6)	22 (1.3)	16 (2.4)	3 (1.3)	6 (2.2)	0.219
Heart conditions	28 (1)	16 (0.9)	6 (0.9)	2 (0.9)	4 (1.5)	0.844
Kidney disease	6 (0.2)	2 (0.1)	1 (0.1)	0 (0)	3 (1.1)	0.008
Liver disease	15 (0.5)	4 (0.2)	6 (0.9)	2 (0.9)	3 (1.1)	0.075

Missing^	44 (1.5)					
COVID-19 Testing Location						<.001
At home	469 (16)	312 (18.1)	117 (17.3)	19 (8)	21 (7.5)	
Walk in clinic	361 (12.3)	198 (11.5)	73 (10.8)	34 (14.3)	56 (20.1)	
Emergency department	73 (2.5)	29 (1.7)	14 (2.1)	11 (4.6)	19 (6.8)	
Hospital	218 (7.4)	121 (7)	51 (7.6)	22 (9.3)	24 (8.6)	
Drive up testing site	1621 (55.4)	974 (56.4)	375 (55.6)	131 (55.3)	141 (50.5)	
Other	177 (6)	94 (5.4)	45 (6.7)	20 (8.4)	18 (6.5)	
Missing^	9 (0.4)					
Hospitalization for SARS-CoV-2						<.001
Not hospitalized	2779 (94.9)	1678 (97.7)	641 (95.7)	219 (94.8)	241 (89.3)	
Hospitalized	110 (3.8)	40 (2.3)	29 (4.3)	12 (5.2)	29 (10.7)	
Missing^	39 (1.3)					
Vaccination Status before SARS-CoV-2 Infection						<.001
Unvaccinated	535 (18.3)	288 (21.2)	103 (19.7)	46 (24)	98 (38.4)	
Vaccinated	1792 (61.2)	1070 (78.8)	419 (80.3)	146 (76)	157 (61.6)	
Missing^	601 (20.5)					

186

187 Work Outcomes

188 For missed workdays at three months post-infection, 197 participants (6.7%) missed ≥ 10 workdays,

189 2546 participants (87.0%) missed <10 workdays, 184 participants (6.3%) were not applicable (i.e. did

190 not have work), and 1 participant (0.0%) was missing a response. For return to work at three months

191 post-infection, 386 participants (13.2%) did not return to work, 2388 participants (81.6%) returned to

192 work, and 154 participants (5.3%) were missing responses. The unadjusted bivariate analyses showed

193 that participants with \geq 5 symptoms had significantly higher odds of missing \geq 10 workdays (18.8%) than

194 participants with fewer (7.6-12.7%) or no symptoms (4.5%) at three months. Similarly, the unadjusted

195 bivariate analyses showed that participants with ≥ 5 symptoms were significantly more likely to not

return to work (27.8%) compared to participants with fewer (15.1-16.3%) or no symptoms (10.5%) at

three months.

After adjusting for participants' sociodemographic and history of clinical conditions, participants
 with ≥5 symptoms had the greatest odds of missing ≥10 workdays and not returning to work compared

200	to those with fewer or no symptoms at three months (Figure 2). For participants with ≥ 10 missed
201	workdays, there was a "dose-response" relation to number of symptoms: Compared to participants with
202	no symptoms at three months, the odds of missing ≥ 10 workdays was two times higher in participants
203	with 3-4 symptoms (adjusted odds ratio [aOR]=1.94, 95% CI: 1.08-3.49) and nearly three times higher
204	in participants with \geq 5 symptoms (aOR=2.96, 95% CI: 1.81-4.83). The difference in odds of missed
205	workdays was not significant among participants with 1-2 symptoms compared to those with no
206	symptoms at three months (aOR=1.58, 95% CI: 0.998-2.49). Compared to participants with no
207	symptoms at three months, the odds of not returning to work were higher in participants with ≥ 5
208	symptoms (aOR=2.44, 95% CI: 1.58-3.76) and in participants with 1-2 symptoms (aOR=1.74, 95% CI:
209	1.23-2.47). The difference in odds of not returning to work was not significant among participants with
210	3-4 symptoms compared to those with no symptoms at three months (aOR=1.25, 95% CI: 0.73-2.14).
211	

212 **Discussion**

The presence of SARS-CoV-2 symptoms three months after acute infection was pervasive and was associated with greater odds of work loss at three months in a prospective registry of people with an initial SARS-CoV-2 infection. This association was especially pronounced among adults with a greater symptom burden (\geq 5 symptoms) at three months, who experienced two to three-fold increased risk of substantial missed workdays and not returning to work compared to adults whose symptoms resolved by three months.

Our work extends prior literature in a few notable ways. First, by capturing clinical information beyond the acute SARS-CoV-2 infection period and including primarily adults with milder disease, the relationships identified in the INSPIRE registry are likely more generalizable to working U.S. adults than prior work in more limited populations. In addition, because the INSPIRE registry includes baseline

223 and longer-term follow up data, this analysis supports temporally connecting persistent SARS-CoV-2 224 symptoms to long-term work outcomes. Second, the consistent relationship between increased three-225 month symptom burden and worse work outcomes further bolsters the likelihood that health effects of 226 post-COVID conditions are sufficient to explain the well-documented relationship between health and 227 work status. Lastly, the broad enrollment period of the INSPIRE registry between December 2020 and 228 August 2022 demonstrates the durability of these findings despite the likely heterogeneous effects of 229 SARS-CoV-2 infection upon work alongside evolving variants, severity of disease, vaccination and 230 treatment.

231 Given high SARS-CoV-2 vaccination rates (77% among participants with non-missing data) and 232 the mild disease course observed in this cohort, the magnitude of work loss is striking. Extrapolating to 233 208 million adults working in the U.S., of whom at least 42% are estimated to have been infected with 234 SARS-CoV-2 as of May 2022 [15], our data suggest that symptomatic SARS-CoV-2 infection may have 235 contributed to over 12.9 million individuals not returning to work within three months of infection, of 236 whom 2.4 million may have post-covid conditions. Given the disproportionate burden of SARS-CoV-2 237 infection observed among workers in public-facing industries, such as education and healthcare, the 238 economic impacts of Long COVID may be disproportionately distributed across the nation [16]. 239 As with all studies, this analysis has limitations. First, estimates may overattribute work loss due 240 to SARS-CoV-2 as our analysis did not include COVID-negative participants and other pandemic-

related causes. Second, our analyses considered each symptom equally, which may not capture nuanced relationships between symptom type, symptom severity and work outcomes. Third, survey questions and responses were developed iteratively in response to the changing landscape of the pandemic, and analysis was limited by survey design and available data. Lastly, there is risk of residual confounding as

we were not able to adjust for all covariates, such as disability, which were found correlated with thecovariates included and outcomes.

247

248 Conclusion

Findings suggest that prolonged SARS-CoV-2 symptoms are common, affecting 4-in 10 participants at three months post-infection and are associated with increased odds of work loss, with the most pronounced work loss association among adults with ≥5 at three months. As data characterizing the numerous health and well-being impacts of Long COVID emerge, despite efforts to "return to normal," policymakers must consider the clinical and economic implications of the COVID-19 pandemic on people's employment status and work absenteeism and strategies for reducing absenteeism.

255

256 Acknowledgements

We would like to thank the California Department of Public Health, CTSI COVID Clinical Research
Steering Committee, CTSI Office of Clinical Research Patient Navigation Team, and Bioinformatics
Program Public Health Seattle King County for their assistance with participant recruitment. We would
also like to thank the University of Washington Institute of Translational Health Sciences (ITHS) for
support of the REDCap instance and for biomedical informatics resources used by the UW Clinical Core
and Enrolling Site to enable study recruitment, which is funded by the National Center for Advancing
Translational Sciences of the National Institutes of Health under award number UL1TR002319.

264

265 **References**

266

- The Labor Supply Rebound from the Pandemic. The White House. 2023 Apr 17. Available from: <u>https://www.whitehouse.gov/cea/written-materials/2023/04/17/the-labor-supply-rebound-from-the-pandemic/</u>
 270
- Maria Ramos. Employment recovery continues in 2021, with some industries reaching or exceeding their prepandemic employment levels," Monthly Labor Review, U.S. Bureau of Labor Statistics, May 2022, <u>https://doi.org/10.21916/mlr.2022.15</u>
- Bairoliya N, Imrohoroglu A. Macroeconomic consequences of stay-at-home policies during the COVID-19 pandemic. Eur Econ Rev. 2023;152:104266.
- Béland, Louis-Philippe and Brodeur, Abel and Brodeur, Abel and Wright, Taylor, Covid-19, Stay-at-Home Orders and Employment: Evidence from CPS Data. IZA Discussion Paper No. 13282, Available at SSRN: https://ssrn.com/abstract=3608531 or http://dx.doi.org/10.2139/ssrn.3608531
- 5. Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications.
 J Neurol Sci. 2021;426:117486.
- 286 6. Goda GS, Soltas EJ. The impacts of Covid-19 absences on workers. J Public Econ.
 2023;222:104889.
- 7. Post-COVID Conditions: Information for Healthcare Providers. Centers for Disease Control and
 Prevention: 2023 Sep 11. Available from: <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-</u>
 care/post-covid-conditions.html
- 292

295

299

274

277

281

285

288

- 8. Post COVID-19 condition (Long COVID). World Health Organization: 2022 Dec 7. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
- 9. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID". Centers
 for Disease Control and Prevention; 2022 Jun 22. Available from:
 https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
- 300 10. Ziauddeen N, Pantelic M, O'Hara ME, Hastie C, Alwan NA. Impact of long COVID-19 on work: a
 301 co-produced survey. Lancet. 2023;402 Suppl 1:S98.
- 302
- 303 11. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in
 304 an international cohort: 7 months of symptoms and their impact. EClinicalMedicine.
 305 2021;38:101019.
- 306

307 308 309	12. Shining a Light on Long COVID: An Analysis of Workers' Compensation Data. The New York State Insurance Fund. 2023 Jan 24. Available from: <u>https://ww3.nysif.com/-</u> /media/Files/NYSIF_Publications/PDF/NYSIFLongCOVIDStudy2023.ashx
310 311 312 313 314 315	 O'Laughlin KN, Thompson M, Hota B, Gottlieb M, Plumb ID, Chang AM, et al. Study protocol for the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One. 2022;17(3):e0264260.
316 317 318 319 320	14. Gottlieb M, Wang RC, Yu H, Spatz ES, Montoy JCC, Rodriguez RM, et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clin Infect Dis. 2023;76(11):1930-41.
321 322 323 324 325	 Akinbami LJ, Kruszon-Moran D, Wang CY, Storandt RJ, Clark J, Riddles MK, et al. SARS-CoV-2 Serology and Self-Reported Infection Among Adults - National Health and Nutrition Examination Survey, United States, August 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1522- 5.
326 327 328	 Kromydas T, Demou E, Edge R, Gittins M, Katikireddi SV, Pearce N, et al. Occupational differences in the prevalence and severity of long-COVID: analysis of the Coronavirus (COVID-19) Infection Survey. Occupational and Environmental Medicine [Internet]. 2023 Oct 1;80(10):545–52.
329 330	Supporting Information
004	

- **S1 Fig. This is the S1 Fig Title.** This is the S1 Fig legend.
- **S2 Fig. This is the S2 Fig Title.** This is the S2 Fig legend.
- **S1 Table. This is the S1 Table Title.** This is the S1 Table legend.
- **S1 File. This is the S1 File Title.** This is the S1 File author group.

Outcome	No. of Symptoms	Total No.	No. of Cases (%)	<i>p</i> -value (χ2)	Adjusted O	dds Ratio (95% CI)		
	0	1637	73 (4.5)	<.001	reference			
	1-2	629	48 (7.6)		1.58 (0.998-2.49)			
10+ missed workdays	3-4	221	28 (12.7)		1.94 (1.08-3.49)	·•	-	No. of Symptoms • 1-2
workdays	5+	256	48 (18.8)		2.96 (1.81-4.83)			• 3-4
	Overall	2743	197 (7.2)		N/A			• 5+
	0	1632	171 (10.5)	<.001	reference	⊷ —		Statistical Significance
Did not	1-2	640	104 (16.3)		1.74 (1.23-2.47)			 p < 0.05 p ≥ 0.05
return to work	3-4	225	34 (15.1)		1.25 (0.73-2.14)	—		
	5+	277	77 (27.8)		2.44 (1.58-3.76)			
	Overall	2774	386 (13.9)		N/A 0	1 2 3 4	5	

Figure 2




Figure 1